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JOURNALS: A CROSS-SECTIONAL STUDY.  
Jessica E. Becker, Harlan M. Krumholz, Gal Ben-Josef, and Joseph S. Ross. 
Section of General Medicine, Department of Internal Medicine, Yale 
University School of Medicine, New Haven, CT.  
 
In 2007, the FDA Amendments Act expanded requirements for ClinicalTrials.gov, 
a public clinical trial registry maintained by the U.S. National Library of Medicine, 
mandating results reporting within 12 months of trial completion for all FDA regulated 
drugs. We compared clinical trial results reported on ClinicalTrials.gov with 
corresponding published articles. We conducted a cross-sectional analysis of clinical 
trials published from July 1, 2010 through June 30, 2011 in high impact journals (impact 
factor ≥10) that were registered and reported results on ClinicalTrials.gov. We 
compared trial results reported on ClinicalTrials.gov and within published articles for the 
following: cohort characteristics, trial intervention, primary and secondary efficacy 
endpoint definition(s) and results, and adverse events. Of 95 included clinical trials 
registered and reporting results on ClinicalTrials.gov, there were 96 corresponding 
publications, among which 95 (99%) had at least one discrepancy in reporting of trial 
details, efficacy results, or adverse events between the two sources. When comparing 
reporting of primary efficacy endpoints, 132 (85%) were described in both sources, 14 
(9%) were described only on ClinicalTrials.gov, and 10 (6%) only within articles. Results 
for 30 of 132 (23%) primary endpoints could not be compared because of reporting 
differences between the two sources (e.g., tabular versus graphics); among the 
 
 
remaining 102, reported results were discordant for 21 (21%), altering interpretations 
for 6 (6%). When comparing reporting of secondary endpoints, 619 (30%) were 
described in both sources, 421 (20%) were described only on ClinicalTrials.gov, and 1049 
(50%) only within articles. Results for 228 of 619 (37%) secondary endpoints could not 
be compared; among the remaining 391, reported results were discordant for 53 (14%). 
Among published clinical trials that were registered and reported results on 
ClinicalTrials.gov, nearly all had at least one discrepancy in reported results, including a 
fifth among primary endpoints. Our findings question the accuracy of both sources and 
raise concerns about the usefulness of results reporting to inform clinical practice and 
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A. Evidence-Based Medicine: A History 
 
Evidence-based medicine has become the approach of modern physicians in 
delivering top-notch patient care. Defined as “the conscientious, explicit, and judicious 
use of current best evidence in making decisions about the care of individual patients,”1 
evidence-based medicine emphasizes combining clinical judgment from experience with 
individual patients with data from studies that illuminate disease pathology and the 
safety and efficacy of medical interventions. It calls for “weighing the pros and cons of 
different treatments fairly.”2 While the term “evidence-based medicine” was first 
introduced to the modern medical literature in 1991 by Gordon Guyatt of McMaster 
Medical School in Ontario, Canada,3,4 this approach to patient care has been cited as far 
back as the 9th century AD and in 19th century Europe.1,5  Yet, once Guyatt brought the 
term into the literature, the academic importance of evidence-based medicine exploded. 
By 2004, less than fifteen years after the term entered the literature, there were over 20 
textbooks, nine academic journals, and several online tutorials dedicated to promoting 




B. Evidence-Based Medicine: The Importance of Clinical Trials  
In the era of evidence-based medicine, there are several methodologies of 
obtaining clinical data that will be used to inform clinician decision-makers. These 
include retrospective observational studies, case studies, and reviews of basic and 
pathophysiologic research. The paragon of evidence informing practice, however, is the 
randomized, controlled clinical trial.1,6-8 Indeed, since 1962, the United States Food and 
Drug Administration (FDA) has regulated the approval of drugs on the basis of efficacy 
and safety data from “adequate and well-controlled” clinical trials.9 Moreover, 
approximately 20,000 new clinical trials of drugs and medical devices are registered 
each year in the United States.10 These clinical trials represent a large investment in 
both the public and private sphere. A 2006 Lancet study of 28 Phase III randomized 
clinical trials funded by the NIH, for instance, found the cost of each trial ranged from 
$722,000 to $64 million,11 or about $12 million per trial.12  
 
C. Clinical Trial Results Dissemination 
Clinical decision-making in a world of evidence-based medicine is complicated 
and depends not only on physicians’ access to the most up-to-date data on drug safety 
and effectiveness, but also on habit, personal experience, colleague experience, patient 
preference, cost concerns, and other factors.13,14 It may be argued, however, that 
whereas physicians’ personal experience with a medication or technology may play 
heavily into the decision to stop using it in practice, the adoption of a new medication or 
technology relies heavily on evidence and knowledge transfer, as the physician has no 
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personal experience with it.15 In a treatise on the diffusion, dissemination, and 
implementation of medical research into clinical decision-making, Lomas describes that 
the steps of first making clinical trial data available, the subsequent analysis of the data 
through meta-analysis and consensus statements, and ultimately the behavioral change 
of physician decision-makers in their prescribing decisions is a process in which each 
step relies on the previous step.14 Thus, though not sufficient to alter physicians’ 
medical decisions, the availability – or diffusion – of clinical data is a necessary step to 
altering physicians’ medical decisions.14 Furthermore, because “research information…is 
the core building block around which further efforts will be built,” Lomas argues that 
“extensive attention” must be paid to the “validity and reliability of the research 
information.”14 Thus, without disregarding the importance of factors like physicians’ 
willingness to change, patient preference, and clinical context of physician decision-
making,13 it is the availability of safety and efficacy information on drugs and medical 
innovations – which come from clinical trials – that is key to physician decision-making 
and that forms the basis of evidence-based medical practice. 
It usually takes the results of more than one trial to truly influence medical 
practice.16 Rather than read through each new trial and analyze data individually, 
however, most physicians rely on guidelines, consensus statements from professional 
organizations, and meta-analyses to summarize and recommend new treatment 
options.13,14,17 In fact, while it has been demonstrated that a single clinical trial may not 
change clinical decision-making,18 recommendations put forth in consensus statements 
have been estimated to have a conformation rate among physician decision-makers 
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averaging around 50 to 60 percent.18 Moreover, policymakers generally assume that 
guidelines put out by professional organizations will serve to spread new knowledge 
about the effectiveness and safety of treatments.15 For instance, in the case of a new 
recommendation from the U.S. Preventive Services Task Force (USPSTF) against the use 
of prostate-specific antigen (PSA) as a screen for prostate cancer, Sen demonstrated 
that PSA provision and ordering by physicians dropped substantially after the 
recommendation release.15  
In addition to demonstrating the effect of this institutional recommendation in 
altering physicians’ behavior, Sen went on to demonstrate that physicians rely on one 
another for practice decisions as well, by showing that the use of PSA by physicians in 
the same group or practice as a given physician was significantly and positively 
associated with PSA use by that physician.15 Nair et al. also find that the prescribing 
behavior of expert “opinion leaders” has a significant impact on other physicians’ 
behavior within their networks – but only after new clinical guidelines are introduced.19 
These studies indicate the importance of clinical evidence and its review by professional 
organizations in driving not only individual physician decision-making, but also driving 
decision-making among physician peers, which has safety and cost implications for an 
even greater swath of patients. Given the widespread dissemination and influence of 
clinical guidelines and their effect on medical decision-making, the full data picture must 
be used by experts in order to develop the guidelines. While efforts have been made to 
ensure the high quality of evidence that goes into consensus statements and 
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guidelines,20 it is equally important to ensure that complete evidence is available to 
guideline-makers and individual physicians alike.  
 
D. Publication Bias 
Throughout recent history, the main venue for accessing clinical trial results has 
been in peer-reviewed medical journals.21,22 Ideally, for full efficacy and safety 
information to reach the prescribing clinician decision-makers and professional 
organizations creating clinical guidelines, all clinical trial results would be published 
completely and accurately in the medical literature.8 Unfortunately, however, a growing 
body of literature has indicated this is rarely the case. Frequently, the studies published 
are only those with significant or positive results, a phenomenon termed “publication 
bias.”23-32  
The earliest modern evidence for this phenomenon comes from a 1959 paper by 
Sterling, who demonstrated evidence of an unexpectedly large amount of studies with 
statistically significant results in four psychology journals.30 More recently, many studies 
have continued to show that positive studies are more likely to be published than 
negative studies.7,23,25-28,30-33 One way of demonstrating publication bias is through 
analysis of meeting abstracts, which has shown that clinical trial abstracts with positive 
results are more likely to be published in full after the meeting.2,34,35 Another insight into 
publication bias comes from looking at the length of time to publication. Among mostly 
industry-funded research, it has been repeatedly found that 25% to 50% of clinical trials 
are not published after several years. 7,22,31,33,36-40 Even among publicly-funded trials, 
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Ross et al. demonstrated that only 46% of a cross-section of NIH-funded clinical trials 
were published within 30 months of trial completion, with 68% published overall after a 
median of 51 months after study completion.22 Moreover, multiple studies have shown 
that time from trial completion to manuscript submission and to publication are 
significantly faster among studies with positive results as compared to those with 
negative results.7,28,32,39 Thus, a large share of the results from clinical trials of drugs and 
devices, and particularly negative results, are delayed or never make it into the medical 
literature, where they have the potential to impact healthcare decision-making.  
Reasons for not publishing may include, but are not limited to, selective 
publication, bias against reporting or publication of negative results, limited resources, 
and a desire to publish “attention-grabbing” results – all both on the part of 
investigators and of journal editors.2,7,22,36,37,41 Though journal editors play a role in 
encouraging the publication of positive results, some evidence has demonstrated that 
studies more often remain unpublished because they are never submitted, rather than 
because they are rejected by reviewers.7,26 Selective publication, however, may also be 
attributed to censorship by study sponsors, particularly in the case of pharmaceutical 
trials that are funded by the drug or device manufacturer as compared to an outside 
funding source.2  
 
E. Outcome Reporting Bias 
Even among clinical trials that are published, however, bias can exist in the data 
that are available in the literature. Among such trials, the phenomenon of “outcome 
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reporting bias” – when only specific outcomes are included in the publication – has 
become increasingly recognized and problematic to a transparent medical evidence 
base.7,42,43  
As far back as 1986, Robert Simes used results from a clinical trial registry and 
from the published literature to demonstrate differences in the suggested efficacy of 
two chemotherapeutic agents.29 He looked specifically at trials registered in the 
International Cancer Research Data Base (ICRDB), which at the time contained most 
cancer-related clinical trials funded by the NIH. He reviewed the ICRDB registry, along 
with the published literature, to examine the use of combination chemotherapy and 
single agent therapy in two kinds of cancer. In each case, he performed a pooled 
analysis and demonstrated that clinical trial results in the literature showed significant 
benefits with the use of each of the combination chemotherapeutic regimens as 
compared to the single alkylating agent. Pooling the results from the trial registry, 
however, demonstrated no effect, or less of a positive effect, of the combination 
chemotherapy as compared to the single agent regimen. Thus, he demonstrated a 
selection bias in the publication of the outcomes previously registered in ICRDB that led 
to a rosier picture of combination chemotherapy accessible to clinicians through the 
medical literature than the data truly suggested.  
Outcome reporting bias is not limited to the oncologic literature, however. While 
the CONSORT Statement, first created in 1996 and updated as recently as 2010, lays out 
guidelines for effectively and transparently publishing clinical trial data, selective 
outcome reporting has continued to be demonstrated widely among published clinical 
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trial reports.8,44 In more recent studies comparing data submitted to the FDA to the 
published literature, important safety and efficacy information of drugs across a variety 
of medical fields have repeatedly found to be lacking from the published 
literature.37,41,45,46   
The first systematic, comprehensive look at the issue of outcome reporting bias 
in the literature came in 2004 from Chan et al., who compared trial protocols submitted 
for Ethics Committee approval between 1994 and 1995 to the same trials published as 
journal articles between 1995 and 2003.42 The group found that a striking 71% of trials 
had at least one efficacy or safety outcome listed in the trial protocol that went 
unreported in the corresponding publication; additionally, 62% had “major 
discrepancies” between the primary endpoints laid out in the protocol and those 
described in the corresponding publication.42 Such discrepancies suggest that 
investigators or journal editors are shaping the medical literature to promote particular 
outcomes, rather than allowing for the complete results to be analyzed in clinical 
decision-making. Indeed, in this study, Chan et al. also surveyed trial authors, who cited 
lack of statistical significance, journal space constraints, and low clinical importance as 
the reasons that outcomes were selectively published.42 These reports were consistent 
with the study’s finding that statistically significant outcomes were more than twice as 
likely to be fully published than those that were not statistically significant, again 
directly impacting the available medical evidence base to imply more positive drug 
effects than the full data may really indicate.42  
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Chan and Altman went on to perform an additional study with quite similar 
results, examining primary and subsequent publications of clinical trials to identify 
outcomes reported in the Methods section of at least one publication whose results 
were never published in a Results section.47 Chan et al. additionally demonstrated 
similar findings among a sample of exclusively federally-funded trials in Canada, with 
88% of trials having at least one outcome going unreported in the publication and 40% 
with discordant primary outcome specification between the trial protocol and 
publication.48 This study indicated that, though financial incentives may play into the 
desire to report only certain efficacy and safety outcomes in the published literature,16 
selective outcome reporting is not limited to industry-funded trials.  
In 2008, Turner et al. built on Chan’s work, examining phase 2 and 3 trials of 12 
antidepressant medications that received FDA approval between 1987 and 2004.37 The 
group examined data submitted to the FDA for marketing approval of these 12 
medications, using the pre-specified trial protocols to evaluate the selective publication 
of outcomes of those trials in the published literature.37 Turner uncovered wide-ranging 
bias – including significantly higher rates of publication of trials with outcomes deemed 
“positive” by the FDA as compared to those deemed “negative,” as well as the spinning 
of results deemed “negative” by the FDA as positive in the literature.37 In fact, the team 
found that results found to be positive by the FDA were 12 times as likely to be 
published in agreement with the FDA analysis as compared to those deemed negative or 
neutral by the FDA.37 The group went on to analyze how these discrepancies could pose 
a threat to the validity of the studies in the published literature and found that tactics to 
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distort the results included using higher patient populations in the published sources; 
increasing the effect size, with a median increase of 32%; and omitting or altering the 
primary outcome from that pre-specified in the FDA protocol when publishing those 
with an initially negative finding.37 Thus, this analysis further uncovered the threat to 
the sanctity of science and the validity of the published literature when outcomes are 
specifically selected to represent a story that may not be comprehensive and may even 
be false. 
Beyond these studies, others have found extensive evidence of outcome 
reporting bias across medical specialties and countries. Ewart et al. compared trials 
published in high-impact journals from late 2006 through early 2007 to entries in clinical 
trial registries and found that nearly one-third had a change in the primary endpoint, 
with the change most often being deletion.49 In a sample of trials published in high-
impact journals in the fields of cardiology, rheumatology, and gastroenterology and 
registered in a trial registry, largely of which was ClincalTrials.gov, Mathieu et al. 
demonstrated that the primary trial outcomes registered varied from those that were 
published in approximately 30% of trials; this number was consistent across general 
medical and specialty journals and was similar to that found by Ewart et al.49,50 Fifteen 
percent of the trials in this study had a primary outcome listed in the protocol that was 
omitted from the publication.50 While only half of the discrepancies could be assessed 
for clinical impact, of those that could, over 80% favored the reporting of a statistically 
significant outcome in the publication, thus indicating the same bias that has been 
demonstrated elsewhere.50 Dwan et al. found a higher rate of primary outcome 
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inconsistency, 47 to 74 percent, in their review of studies examining outcome reporting 
bias that compared trial protocols to publications.7 Two additional studies have also 
demonstrated selective outcome reporting by showing significantly more complete 
reporting of efficacy and safety results in trial registry entries as compared to 
publications in a German sample and in a sample with registry entries on 
ClinicalTrials.gov, respectively.51,52 Finally, Vedula et al. were able to go a step further 
beyond trial protocols or registry reports to access internal documents from Pfizer and 
Parke-Davis for trials of off-label use of gabapentin; they found that 8 of the 12 trials 
that were published had a discordant primary outcome between the internal document 
and the publication, thus demonstrating an even deeper-rooted issue in selective 
outcome reporting.53  
These studies highlight that, among a range of sources and medical specialties, 
outcome reporting bias exists in the accessible medical literature and often exaggerates 
the efficacy or safety of drugs. The lack of reporting, or altered reporting, of primary 
endpoints in the published literature as compared to pre-specified protocols and 
registry entries is particularly troubling, as trials are designed with statistical power to 
address these outcomes as initially designated. Thus, the results of an altered primary 
outcome when published may not be as statistically reliable. Additionally, patients sign 
up for, and funders invest in, trials with particular clinical aims. Altering the primary 
endpoint for publication can prevent advancement and true understanding in clinical 
science to allow instead for the perceived advancement of academic or financial 
interests when publishing more positive results. 
 
 12 
E. The Problem with Bias  
Despite the mounting evidence that negative results are not published, at both 
the study- and outcome-level, physicians and the institutions crafting clinical guidelines 
need access to both positive and negative results in order to make fully informed, 
evidence-based clinical decisions and recommendations.54 In fact, negative results are 
instrumental in helping physicians to evaluate the medications they currently have at 
their disposal and to “invalidat[e] previously accepted” medication usage.1,31 
Additionally, literature reviews and meta-analyses depend on fully informed data.2,36,41 
If trials or outcomes are selectively published, the numbers of patients can be difficult to 
glean when using the published literature for meta-analysis or literature review.55 
However, the complete story – positive and negative results – can only be revealed in 
the setting of publication bias if clinical trial data can be freely accessed by clinicians 
through mechanisms other than the published literature. 
In addition to improving the quality and efficiency of evidence-based clinical 
decision-making, other factors necessitate the public dissemination of clinical trial data. 
Perhaps the most important of such factors is the ethical consideration to trial 
participants.2,16,31,54,56 When patients participating in clinical trials give their time – and 
their bodies – to research investigators, they generally do so with the assumption that 
their donation of time and self will help to improve medical care for others. If the data 
obtained from these patients are not fully or accurately conveyed to clinical decision 
makers, the patient’s donation is for naught. Further, public dissemination of trial 
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results may also improve the trust of the general public in medical science as an 
institution.56  
On top of clinical and ethical concerns, unpublished clinical trial results represent 
a sunken investment. The cost of an individual phase III clinical trial has been estimated 
in the hundreds of millions of dollars.57 The National Institutes of Health (NIH) spends 
over $3.5 billion of public funds on investments in clinical trials.22 Thus, there is an 
additional obligation from investigators funded by public sources to disseminate their 
trial results in a freely-accessible, public setting.2 Whether publicly- or privately-funded, 
unpublished research can also lead to the unbeknownst duplication of clinical trials, 
further increasing the cost burden to the health care system.58 
 
F. Policies to Address Bias: Clinical Trial Registration and Results Reporting 
To tackle the issues of selective publication and publication bias, evidence-based 
medicine experts have long supported the creation of broad-ranging public clinical trial 
registries, with the goal of prospectively registering basic information about trials at trial 
inception.2,29,31,55,56,58,59 As such, trial investigators and sponsors can be more readily 
held accountable for not disseminating trial information and selectively reporting 
results. While clinical trial registries have existed in one form or another since at least 
the mid-1970s, the initial registries were generally specialty-specific, incomplete, and 
difficult to access.60,61 The advent of the Internet age, however, has allowed for the 
creation of online clinical trial registries, with the potential to disseminate all clinical trial 
results in a complete and easily-accessible manner.60  
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In 1997, the United States Congress passed the FDA Modernization Act (FDAMA), 
mandating the Department of Health and Human Services, acting through the NIH, to 
develop a public, Internet-based clinical trial registry, or “data bank[,]…of information 
on clinical trials for drugs for serious or life- threatening diseases and conditions” 
submitted to the FDA as part of Investigational New Drug (IND) applications.62,63 This law 
compelled the U.S. Department of Health and Human Services to create a public registry 
of ongoing, federally- and privately-funded clinical trials of drugs in the U.S. The law was 
intended to provide a publicly-available listing of ongoing trials for patients who wished 
to enroll, particularly those with rare illnesses who otherwise may not have knowledge 
or access to groundbreaking treatments for their conditions. In addition to providing 
information for patients, however, the registry was a first step in holding trial 
investigators and sponsors accountable for providing public access to trial information, 
an early step to improve transparency in the publicly-accessibly medical evidence base. 
The initial requirements for the data bank, as laid out by the law, included:
“(A) A registry of clinical trials (whether federally or privately funded) of 
experimental treatments for serious or life-threatening diseases and 
conditions… Information provided shall consist of eligibility criteria for 
participation in the clinical trials, a description of the location of trial 
sites, and a point of contact for those wanting to enroll in the trial, and 
shall be in a form that can be readily understood by members of the 
public… (B) Information pertaining to experimental treatments for 
serious or life-threatening diseases and conditions that may be 
available-- (i) under a treatment investigational new drug application 
that has been submitted to the Secretary under section 561(c) of the 
Federal Food, Drug, and Cosmetic Act; or (ii) as a Group C cancer drug 
(as defined by the National Cancer Institute). The data bank may also 
include information pertaining to the results of clinical trials of such 
treatments… including information concerning potential toxicities or 
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adverse effects associated with the use or administration of such 
experimental treatments.”63 
 
Thus, on top of requiring basic information about each trial, the law suggests but did not 
explicitly mandate the reporting of trial results and adverse events. Notably, device 
trials were excluded from these mandates, with the explicit statement in the law that 
including devices would be considered and possibly added.63  
As a result of these requirements set out in FDAMA, the U.S. National Library of 
Medicine launched a public, Internet-based clinical trial registry, ClinicalTrials.gov, in 
2000. As laid out in the law, the registry was created on behalf of the National Institutes 
of Health, under the Department of Health and Human Services. In addition to IND-
related trials, the new ClinicalTrials.gov database allowed for the registration of any 
clinical trial, regardless of intervention kind, medical condition, or country of 
investigation; and within five years, the ClinicalTrials.gov database contained over 
20,000 trial entries.62 While other trial registries had been in place and subsequently 
developed, including the WHO’s International Clinical Trial Registry Platform, 
ClinicalTrials.gov has remained the largest and most prominent such registry in the 
United States.54,56,60,61 While ClinicalTrials.gov did not initially require trial results to be 
registered, the suggestion of including results laid out in FDAMA set the groundwork for 
a potential publicly-available register of clinical trial results, which would later be 




In 2005, the International Committee of Medical Journal Editors (ICMJE), a group 
of general medical journal editors who work to set recommendations for the conduct 
and publication of medical research,64 initiated a policy that all trials being considered 
for publication in one of its member journals must be registered in a public clinical trial 
registry at or before patient enrollment.16 This move came explicitly in an attempt from 
journal editors to start addressing the issues of publication and outcome reporting bias 
and to improve clinical trial data transparency, with the policy announcement noting the 
“ideal” that eventually “if all trials are registered in a public repository at their inception, 
every trial’s existence is part of the public record, and the many stakeholders in clinical 
research can explore the full range of clinical evidence.”16 The ICMJE defined clinical trial 
at the time as “any research project that prospectively assigns human subjects to 
intervention or comparison groups to study the cause-and-effect relationship between a 
medical intervention and a health outcome.”16 At the time, ClinicalTrials.gov was, to the 
knowledge of the ICMJE, the only established eligible registry fitting all requirements 
laid out in their new policy, such as being freely accessible, open to all registrants, run 
by a non-profit, and electronically searchable.16 Despite concerns from trial investigators 
that this requirement would be taxing and eliminate competition,16 the number of 
clinical trials registered in ClinicalTrials.gov jumped over 70% from 13,153 in the months 
preceding the announcement to 22,714 trials just one month after the policy went into 
effect in September 2005.56,62  
In 2007, the ICMJE reevaluated this policy. At this time, the ICMJE broadened the 
definition of clinical trial to that being used by the World Health Organization (WHO) – 
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“any research study that prospectively assigns human participants or groups of humans 
to one or more health-related interventions to evaluate the effects on health 
outcomes”56 – in order to include preliminary trials in its mandate and thus in its goal of 
improving trial transparency in the world of evidence-based medicine. The group also 
endorsed the WHO ICTRP and its member registers as acceptable venues for clinical trial 
registration.56 Recognizing a growing advocacy for reporting of clinical trial results to the 
databases in which registration was required, the ICMJE specifically laid out in their 
2007 announcement that “results posted in the same clinical trials registry in which the 
primary registration resides…[would not be considered] to be previous publication if the 
results [we]re presented in the form of a brief (<500 words) structured abstract or 
table.”56 This move encouraged open access to trial results via trial registries while 
reassuring investigators who might participate that their work would still be competitive 
for publication. 
In September of the same year, the U.S. Congress followed suit in utilizing the 
developed ClinicalTrials.gov registry to create a database of publicly-accessible clinical 
trial results, thus expanding the evidence base for clinical decision-making beyond 
publications, by passing the FDA Amendments Act (FDAAA), Section 801.65 FDAAA 
updated the clinical trial registry requirements that had been laid out under the 1997 
FDAMA law. Specifically, FDAAA expanded the requirements to mandate registration by 
trial sponsor or primary investigator at trial initiation for trials not only of drugs, as in 
FDAMA, but also of all biologic agents and medical devices regulated by the FDA and of 
pediatric postmarket surveillance studies required by the FDA.54,63,65,66 Notably, unlike 
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the new ICMJE requirement, FDAAA continues to exclude phase 1 clinical trials and 
“small feasibility studies” from reporting requirements.54,65,66 The law specifies that FDA 
regulation applies to interventional trials with at least one arm; with one or more U.S. 
sites; studying a drug, biologic, or device manufactured in the U.S. or its territories; or 
that are conducted under an investigational new drug application or investigational 
device exemption.65,66 
More important, FDAAA mandates the reporting of the results of such trials 
ongoing on or after September 27, 2007. Specifically, trial results must be uploaded to 
ClinicalTrials.gov within 12 months of study completion, defined as completion of 
collection of the primary endpoint on the final study subject.54,65 The specific data 
elements that are required by this mandate include reporting of: the study design, start 
date, target sample size, and the trial’s primary and secondary outcomes; demographic 
and baseline characteristics of the sample, including enrollment and completion 
numbers; results of the primary and secondary outcomes, including results of tests of 
significance; and serious and frequent adverse events (>5% in any arm of the trial).54,65 
The reporting requirements apply to the trial’s main results, not those of subgroup 
analyses. The law also established penalties for not complying with the reporting of trial 
information and results, including loss of NIH grant funding and fines of up to $10,000 
per day.54,65 Results of trials of FDA-approved drugs being studied for a new, 
unapproved indication have an additional year to report results; there is no requirement 
to post results for drugs that never received FDA approval or for drugs that received FDA 
approval before September 27, 2007 that no longer were the subject of clinical trials – a 
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large majority of prescription drugs currently in clinical practice.54 Nonetheless, through 
this new regulation, the U.S. government took a firm stance in supporting evidence-
based medicine by promoting clinical trial data transparency going forward. The law also 
attempted to increase data clarity by laying out requirements for the Department of 
Health and Human Services to link ClinicalTrials.gov entries to relevant results 
information already available on the Internet through the FDA, National Library of 
Medicine (NLM), or National Institutes of Health (NIH), such as FDA public health 
warnings, FDA drug approval packages, or peer-reviewed articles linked through 
Medline.54,65  
 
G. Initial Evaluation of ClinicalTrials.gov 
The mandated expansion of ClinicalTrials.gov under FDAAA to require results 
reporting for studies investigating medical products created a pool of clinical trial 
findings available to inform clinical practice and research. However, in a careful 
evaluation of the new legislation, Alastair Wood points out that “because the submitted 
data will not be peer-reviewed…interpreted, qualified, or explained, the results reported 
at ClinicalTrials.gov will complement rather than replace the thoughtful presentation 
and discussion of results characteristic of the best peer-reviewed publications.”54 
Nonetheless, given the broad evidence base suggesting publication and outcome 
reporting bias in peer-reviewed publications, ClinicalTrials.gov may very well serve as a 
cache of data that may never make it into the peer-reviewed, published literature. As 
such, analysis of the completeness and accuracy of the contents of the ClinicalTrials.gov 
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registry after the implementation of FDAAA is important to ensure it can be a valuable 
resource for clinicians and researchers.  
Initial studies examining the contents of ClinicalTrials.gov after FDAAA have 
indicated that despite the mandate and the purported penalties for non-compliance, 
fewer than one-quarter of trials required to report results to ClinicalTrials.gov had 
actually done so within a year of trial completion prior to 2011.67,68 However, in 
subsequent years, the number of registered trials reporting results has increased.69 
Previous studies have examined trial information available on ClinicalTrials.gov and 
found fairly complete reporting of mandatory data elements, such as trial funder and 
intervention, but high rates of missing data for optional elements and uncertainty about 
information accuracy.41,50,62 Because results reporting began relatively recently under 
FDAAA, no studies have yet thoroughly examined the completeness and accuracy of this 
information on ClinicalTrials.gov.  
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II. Statement of Purpose 
The purpose of this project is to evaluate the trial data and results reported to 
ClinicalTrials.gov after the passing of the FDA Amendments Act and to examine how 
these data on ClinicalTrials.gov compare to data published in the high-impact medical 
literature for the same trials. While the results reported in either ClinicalTrials.gov or 
published articles have the potential to be incomplete and inaccurate, inconsistencies 
between these two sources of trial results will offer insights into whether and how 
results reported for all trials, published or not, can be used to inform clinical practice 




III. Specific Hypothesis 
The results listed on ClinicalTrials.gov will be fairly complete for required data elements. 
The clinical trial endpoints and results defined and reported on ClinicalTrials.gov will 
vary from those in the published literature, in statistically significant ways, with a bias 





IV. Specific Aims 
Primary Aims: 
1) To examine the completeness of trial results data reported on ClinicalTrials.gov 
as required by FDAAA within 12 months of trial completion.  
a. Specifically, to assess completeness of the following required data 
elements: cohort characteristics; intervention; primary and secondary 
endpoints; results of all primary and secondary endpoints; all serious 
adverse events; and all other adverse events with a frequency ≥ 5% in at 
least one study arm. 
2) To better understand the accuracy of these trial data elements reported on 
ClinicalTrials.gov, as compared to corresponding trial data elements published in 
high-impact biomedical journals.  
 
Secondary Aim:  
1) To use secondary endpoint data reporting on ClinicalTrials.gov and in the 
published literature to evaluate the existence of positive outcome reporting bias 
in the published literature. 
a. Specifically, to evaluate the significance of secondary endpoints listed on 
ClinicalTrials.gov and to correlate secondary endpoint significance as 
listed on ClinicalTrials.gov with publication of the endpoint in the trial’s 
corresponding journal article. 
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V. METHODS  
A. Study Sample  
Using information obtained from the NLM, members of the team (Dr. Ross and 
Gal Ben-Josef) identified all articles published in a Medline-indexed journal between July 
1, 2010 and June 30, 2011 that were linked to a ClinicalTrials.gov identification number 
(n=4,586). These dates were chosen because we wanted to examine a one-year period, 
data collection was set to begin in January 2012, and we wanted to allow for a lag 
period after which investigators published their study to report results to 
ClinicalTrials.gov. The information obtained from the NLM included all reported data 
elements available on ClinicalTrials.gov, such as lead funder, study design, and condition 
studied. From this sample of published clinical trials, Dr. Ross and Ms. Ben-Josef 
identified a sub-sample of articles published in journals with an impact factor ≥ 10 
(n=831), determined using Web of Knowledge (Thomson Reuters; New York, NY). 
Subsequently, we restricted our study to articles describing clinical trials for which 
results had been reported to ClinicalTrials.gov as of January 2012 (n=149). Finally, 
because FDAAA only requires reporting of main trial results, we excluded 53 articles that 




                         
 
Figure 1: Flow diagram showing sample construction of clinical trials registered in and reporting main results on ClinicalTrials.gov 
that were published in a Medline-indexed journal with an impact factor ≥ 10 between July 1, 2010 and June 30, 2011. 
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B. Collecting Reported Information and Values 
All data collection described below was performed by me (Jessica Becker). Gal 
Ben-Josef assisted in data collection from a fraction of the trials. A selection of data was 
also reviewed by Dr. Ross. 
 
i. Cohort Characteristics and Trial Intervention 
For each clinical trial, we collected information from both ClinicalTrials.gov and 
the corresponding publication on cohort characteristics, including enrollment numbers, 
completion numbers, and age and sex distributions, and the trial intervention. We 
considered study intervention information incomplete unless the definition (i.e. name), 
duration, frequency, and dosage of the intervention were each described. 
 
ii. Primary Efficacy and Secondary Efficacy Endpoints 
For each clinical trial, we collected the number of primary and secondary efficacy 
endpoints reported on ClinicalTrials.gov and in the publication along with the definition 
of each endpoint, including time point(s) at which the endpoint was measured and scale 
defined to measure the endpoint’s results (e.g. a 54-point Attention Deficit 
Hyperactivity Disorder rating scale or the defined threshold value for the endpoint). If an 
outcome was reported at multiple time points, we considered each ascertainment point 
separately. Since FDAAA mandates that only endpoints evaluated for the entire study 
population be reported on ClinicalTrials.gov, we did not collect endpoints that were 
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defined only for a subgroup population or extension study endpoints. Next, for each 
endpoint, we collected results values reported on ClinicalTrials.gov and in the 
corresponding publication and noted when values were not reported in one source or 
the other.  
 
iii. Adverse Events 
For each trial, we collected the type and frequency of all serious adverse events 
affecting one or more trial participants and all other adverse events with at least 5% 
frequency in one trial arm from ClinicalTrials.gov and from the corresponding 
publication, in concordance with ClinicalTrials.gov definitions.70  
 
C. Comparing Reported Information and Values  
All data collection and comparisons described below were performed by me 
(Jessica Becker). Gal Ben-Josef assisted in data collection and comparison for a fraction 
of the trials. A selection of data, including all results discordant between sources, was 
also reviewed by Dr. Ross. 
 
i. Cohort Characteristics and Trial Intervention 
For each trial, we compared the reported information for cohort characteristics 
and intervention between ClinicalTrials.gov and corresponding publications, 
determining whether information was concordant, or in agreement. Each cohort 
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characteristic was considered concordant only if the values of the characteristic (e.g. 
number of participants enrolled or mean age) were numerically equal across sources for 
all trial arms. We could not compare cohort characteristics when sources differed in 
statistical analysis method, for instance, if one source reported medians and another 
means. We considered reported study interventions concordant if there was agreement 
in the definition, duration, frequency, and dosage of the intervention between both 
sources.  
 
ii. Primary Efficacy and Secondary Efficacy Endpoints 
For each trial, we compared the reported information for primary and secondary 
efficacy endpoints between ClinicalTrials.gov and corresponding publications. We 
considered endpoint definitions concordant if there was agreement in the described 
endpoint, time of endpoint ascertainment, and endpoint measurement scale between 
both sources.  
For primary and secondary efficacy endpoints that were reported in both 
sources and defined concordantly, we determined whether results values were 
concordant (i.e., numerically equal), discordant (i.e., not numerically equal), or could not 
be verified. We could not verify results values when reporting was numerical in one 
source but graphical in the other, sources differed in statistical analysis method, or 
results were stratified differently between the sources. 
For those primary efficacy endpoints with discordant results values, the medical 
student author of this thesis (myself) and Dr. Ross evaluated the results together to 
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determine whether the publication’s values would lead to a different interpretation 
than the results reported on ClinicalTrials.gov would. We accomplished this by 
examining the magnitude of the difference, directionality of the results, and statistical 
significance testing from each source, when available. We did not examine the impact 
on study interpretation for secondary efficacy endpoint results.  
 
iii. Adverse Events 
For each trial, we compared the reported information for adverse events 
between ClinicalTrials.gov and corresponding publications, determining whether results 
were concordant, discordant, or could not be verified. We considered serious and other 
adverse event reporting concordant only if all serious events in one or more subjects or 
all other events with a frequency ≥ 5% reported within one source were also reported in 
the other, at equal numerical frequency for each event in all trial arms. We could not 
verify adverse event results values when sources used different adverse event reporting 
scales (e.g. serious and other categorization required by ClinicalTrials.gov versus the 
National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] 
5-point graded scale in a publication) or if the publication combined serious and other 




D. Statistical Analysis 
All of the descriptive and statistical analyses described below, including the 
exploratory analysis of secondary endpoints, were performed by me (Jessica Becker), 
with assistance as needed and complete review both provided by Dr. Joseph Ross. 
For sample description purposes, we collapsed the reported data elements 
available on ClinicalTrials.gov into clinically meaningful categories (Table 1). We then 
conducted a descriptive analysis, examining completeness of reported information on 
ClinicalTrials.gov and concordance between ClinicalTrials.gov and corresponding 
publications for trial cohort characteristics; intervention; primary and secondary 
endpoints; primary and secondary endpoint results; all serious adverse events; and all 
other adverse events with a frequency ≥ 5% in at least one study arm. For discordant 
primary endpoint results, we also characterized the frequency with which trial 
interpretation differed between the two sources.  
As an exploratory analysis of secondary endpoints, to determine whether 
favorable secondary endpoints were more likely to be reported in corresponding 
publications, we classified the statistical significance of all secondary endpoints reported 
on ClinicalTrials.gov and examined the likelihood of reporting statistically significant 
endpoints in the corresponding publications using Chi-Square tests. In many cases, 
statistical testing was reported within ClinicalTrials.gov. However, when not reported, 
we performed statistical testing using reported results values, using QuickCalcs t test 
calculator (v3.5.4, GraphPad; La Jolla, CA) for comparisons of continuous endpoints and 
Epi Info™ (v7.1.1.0, Centers for Disease Control; Atlanta, GA) for comparisons of 
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categorical endpoints. A p-value ≤ 0.05 was used as a threshold for statistical 
significance for superiority studies, > 0.05 for non-inferiority studies. 
Descriptive analyses were performed using Excel® (v14.3.1, Microsoft 






A. Study Sample 
We identified 96 trials reporting main results on ClinicalTrials.gov that were 
published in a Medline-indexed journal with an impact factor ≥ 10 between July 1, 2010 
and June 30, 2011. One ClinicalTrials.gov identifier registered a trial conducted in two 
continents, with primary results for each continent published separately; for our 
analysis, these articles were considered to be two separate trials. Industry was the lead 
funder of nearly three-quarters of the trials (n=70; 73%). The most common conditions 
studied were cardiovascular disease, hyperlipidemia, or diabetes (n=21; 22%), cancer 
(n=20; 21%), and infectious diseases (n=19; 20%). Median trial enrollment size was 509 
subjects (Inter-Quartile Range [IQR], 216–1281) and trials were most frequently 
published by New England Journal of Medicine (n=23; 24%), Lancet (n=18; 19%), and 
Journal of the American Medical Association (n=11; 12%). Table 1 below describes the 









Table 1: Characteristics of clinical trials registered on ClinicalTrials.gov with primary results 
published in a biomedical journal with impact factor ≥ 10 between July 1, 2010 and June 30, 
2011.  
Trial Characteristics  
Trial Sponsor, No. (%)  
 Industry 70 (73) 
 NIH or other government agency 9 (9) 
 Non-profit organization or other funding agency 17 (18) 
Phase 3 & 4 trials, No. (%) 68 (71) 
Conditions examined, No. (%)  
 Diabetes, hyperlipidemia, or cardiovascular disease 21 (22) 
 Cancer 20 (21) 
 Infectious diseases 19 (20) 
 Neurologic 9 (9) 
 Hematologic 7 (7) 
 Other conditions 20 (21) 
Trial enrollment size, median (range) 509 (216-1281) 
Corresponding publication journal, No. (%)  
 New England Journal of Medicine 23 (24) 
 The Lancet 18 (19) 
    Journal of the American Medical Association 11 (12) 





B. Data Completion 
All trials reported cohort enrollment, age, and sex distributions in both sources. 
Trial completion rate was explicitly described in both sources, or could be calculated 
from number enrolled and withdrawn, for 90 trials (94%). All trials provided some 
intervention information in both sources; 16 (17%) were missing data on dosage 
amount or timing in at least one source. For primary outcomes, 91 trials (95%) described 
at least one primary efficacy outcome in both sources, whereas 5 (5%) had no primary 
efficacy outcomes in either source, instead defining only primary safety outcomes in 
both sources. Similarly, 94 publications (98%) and 89 ClinicalTrials.gov entries (93%) 
described at least one secondary efficacy outcome, whereas 95 trials (99%) reported 
adverse events in both sources. 
 
C. Overall Registry-Article Comparison 
Overall, 95 of 96 trials were found to have at least one discrepancy between 
results reported to ClinicalTrials.gov and corresponding published articles: 29 (30%) 
discordant trial cohort descriptions; 15 (16%) discordant intervention definitions; 27 
(28%) discordant primary efficacy outcome definitions or results values; 91 (95%) 
discordant secondary efficacy outcome definitions or results values; and 50 (52%) 
discordant adverse events reporting. Table 2 below summarizes the completion and 





Table 2: Reporting and comparison of results information on ClinicalTrials.gov and in 
publications among trials published in a biomedical journal with impact factor ≥ 10 between July 
1, 2010 and June 30, 2011 that were registered and reported results on ClinicalTrials.gov (n=96). 
Results 
Information 
Trials Reporting, No. (%) Comparison of Reported Information 
among Trials Reporting in Both 
Sources, No. (%) 





     
Enrollment No. 96 (100) 96 (100) 94 (98) 2 (2) 0 (0) 
Completion Rate 90 (94) 90 (94) 70 (78) 20 (22) 0 (0) 
Sample Age 
Distribution 
96 (100) 96 (100) 56 (58) 6 (6) 34 (35) 
Sample Sex 
Distribution 
96 (100) 96 (100) 85 (89) 9 (9) 2 (2) 
Trial Intervention 96 (100) 96 (100) 65 (68) 15 (16) 16 (17) 
Efficacy Endpoints      
Primary* 91 (95) 91 (95) 81 (61) 21 (16) 30 (23) 
Secondary† 89 (93) 94 (98) 338 (55) 53 (9) 228 (37) 
* For primary efficacy endpoints, same 91 trials defined a total of 156 primary efficacy endpoints 
in either ClinicalTrials.gov or the corresponding publication, 132 (85%) of which were described 
in both sources. 
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† For secondary efficacy endpoints, 96 trials defined a total of 2089 secondary efficacy 
endpoints in either ClinicalTrials.gov or the corresponding publication, 619 (30%) of which were 
described in both sources. 
 
D. Cohort and Intervention Registry-Article Comparison 
Enrollment size could be compared for all 96 trials and was discordant for 2 (2%), 
varying by 1 to 2 individuals per trial arm. We were able to compare trial completion 
rates for 90 trials with complete information; of these, trial completion was discordant 
for 20 (22%), with a median difference of 10.5 percentage points (IQR: 2.3-31.1). We 
could not compare sex distributions for 2 trials (2%); among the remaining 94, sex 
distribution was discordant for 9 (10%), with a median difference of 0.70 percentage 
points (IQR: 0.17-4.7). We could not compare age distributions for 34 trials (35%); 
among the remaining 62, age distributions were discordant for 6 (10%), varying by a 
median of 0.60 years (IQR: 0.13-1.3). Among 80 trials with complete trial intervention 
descriptions in both sources, 15 descriptions (19%) were discordant, most often because 
of different dosages, different frequencies or duration of intervention, or description of 
an additional intervention or placebo. See Appendix Table A1 for complete 
enumeration of intervention discordances. 
 
E. Primary Outcome Registry-Article Comparison 
Among 91 trials defining primary efficacy endpoints, there were 156 endpoints 
designated within either ClinicalTrials.gov or published articles, 132 (85%) of which were 
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described in both sources, 14 (9%) of which were described only on ClinicalTrials.gov, 
and 10 (6%) of which were described only in articles. The median number of primary 
efficacy endpoints was 1 (IQR 1.0-1.0) per ClinicalTrials.gov entry and 1 (IQR 1.0-1.3) per 
publication.   
Thirty (23%) of 132 concordantly defined endpoints reported results values that 
could not be compared, often due to graphical versus numerical reporting. Among 102 
endpoints that could be compared, results values for 21 (21%) were discordant. 
Therefore, in total, only 81 of 156 endpoints (52%) designated as primary efficacy 
outcomes within either ClinicalTrials.gov or the published article were described in both 
sources and reported verifiable and concordant results. Figure 2 below summarizes the 
findings for primary endpoint reporting. 
Among 21 trials with discordant primary efficacy outcome results values, 
discrepancies led to differences in trial interpretation between sources for 6 (29%; 7% of 
trials with primary efficacy endpoints). An example was reporting of statistically 
different primary outcomes between trial arms on ClinicalTrials.gov but not significantly 
different in the publication.71,72 Table 3 below highlights the primary endpoint results 
discordances that altered trial interpretation.  
For the remaining 15 trials (71%) with discordant primary outcome results 
values, discrepancies did not lead to differences in trial interpretation. For instance, in 
one case, primary endpoint results reported in the paper for the treatment group were 
reported as results for the placebo group on ClinicalTrials.gov, and vice versa;73,74 
however, since the results were not statistically different, trial interpretation was 
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unchanged. In another instance, the discordant primary outcome results were close in 
absolute value, in the same relative directionality between trial arms, and statistically 
significant between trial arms in both sources.75,76 For a complete enumeration of the 
primary endpoint results discordances that did and did not alter trial interpretation, 





Figure 2: Primary efficacy outcome endpoint definitions and results values reported on ClinicalTrials.gov and in corresponding journal articles 
for clinical trials registered in and reporting main results on ClinicalTrials.gov that were published in a Medline-indexed journal with an impact 
factor ≥ 10 between July 1, 2010 and June 30, 2011 (n=91). 
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Table 3: Discordant primary efficacy endpoint results reported on ClinicalTrials.gov and in corresponding publication that altered trial 
interpretation (n=6). 
Trial ID Primary Efficacy Outcome Explanation of Altered Trial 
Interpretation ClinicalTrials.gov Reported Results Publication Reported Results 
NCT00094887 Median Hours to Resolution of Vaso-occlusive Pain Crisis (95% CI) Time to resolution in both groups is 
substantially lower on 
ClinicalTrials.gov than in the article, 
altering clinical interpretation. 
Inhaled Nitric Oxide: 61.83, 95% CI: (41.75, 
78.00); Placebo: 55.16, 95% CI: (46.00, 72.00); No 
statistical analysis provided. 
Inhaled Nitric Oxide: 73.0, 95% CI: (46.0, 91.0); 




Median Time to Progression (95% CI) Median time to progression in both 
groups is substantially higher on 
ClinicalTrials.gov, altering clinical 
interpretation. 
Sorafenib + Doxorubicin: 263 days, 95% CI: (146, 
384); Placebo + Doxorubicin: 147 days, 95% CI: 
(66, 244); P = 0.016 
Sorafenib + Doxorubicin: 6.4 months, 95% CI: 
(4.8, 9.2); Placebo + Doxorubicin: 2.8 months, 




Number of Participants With Recurrence of Major Depression Percentage of participants with 
major depression recurrence is 
lower on ClinicalTrials.gov and 
hazard ratio on ClinicalTrials.gov is 2-
fold greater. 
Donepezil: 19/67, 95% CI: (16, 31); Placebo: 
11/63, 95% CI: (6, 18); HR=3.97, SD=2.09, 95% CI: 
(1.00, 4.41); P=0.05 
Donepezil: 35%; 95% CI: (24%, 46%); Placebo: 
19%, 95% CI: (9%, 29%); HR=2.09, 95% CI: (1.00, 






Progression-free Survival (PFS), median PFS is substantially lower in the 
rituximab arm reported on 
ClinicalTrials.gov than in the article, 
altering clinical interpretation.  
Fludarabine/Cyclophosphamide: 981.0  days, 
Range: (1, 1343); Fludarabine/ 
Cyclophosphamide/Rituximab:  
1212.0 days, Range: (1, 1372); P<0.0001 
Fludarabine/Cyclophosphamide: 32.8 months, 
95% CI: (29.6, 36.0); Fludarabine/ 
Cyclophosphamide/ Rituximab: 51.8 months, 95% 
CI: (46.2, 57.6); P<0.0001 
NCT00404079 
 
Roland Morris Disability Questionnaire, 1 year ClinicalTrials.gov score is higher for 
both trial arms and statistical testing 
results are different in the two 
sources, leading to a difference in 
trial interpretation.  
Glucosamine Sulphate: 9, SD: 4; Placebo: 9, SD: 4; 
Odds Ratio: 4.5 ± 4; P=0.05 
Glucosamine Sulphate: 4.8, 95% CI: (3.9, 5.6); 
Placebo: 5.5, 95% CI: (4.7, 6.4); P=0.50 
NCT00426751 Number of Participants With Complete Sum ST Resolution 60 Min After Percutaneous Coronary 
Intervention (Intent-to-Treat Population) 
Confidence interval of the adjusted 
difference between arms crosses 
zero on ClinicalTrials.gov and does 
not in the article, suggesting a 
difference in statistical testing of 
results between the two sources, 
leading to a difference in trial 
Eptifibatide: 124/214; Abciximab: 103/196; 
Adjusted Difference: 6.8%, 95% CI: (-3.0%, 16.6%) 
Eptifibatide: 62.6%; Abciximab: 56.3%; Adjusted 








F. Secondary Outcome Registry-Article Comparison 
Among the 96 trials, there were 2089 endpoints designated as secondary 
efficacy endpoints within either ClinicalTrials.gov or a published article, 619 (30%) of 
which were described in both sources, 421 (20%) of which were described only on 
ClinicalTrials.gov, and 1049 (50%) of which were described only in the article. There was 
a median of 5 (IQR 2-12) secondary efficacy endpoints per ClinicalTrials.gov entry and 11 
(IQR 7-21) per publication.  
Among the 619 secondary endpoints defined in both sources, results of 228 
(37%) could not be compared, often because results values were not reported within 
ClinicalTrials.gov. Among 391 comparable secondary endpoints, 53 (14%) had discordant 
results. Therefore, in total, only 338 of 2089 endpoints (16%) designated as a secondary 
outcome within either ClinicalTrials.gov or the published article were described in both 
sources and reported verifiable and concordant results. Figure 3 below summarizes the 







Figure 3: Secondary efficacy outcome endpoint definitions and results values reported on ClinicalTrials.gov and in corresponding 
journal articles for clinical trials registered in and reporting main results on ClinicalTrials.gov that were published in a Medline-
indexed journal with an impact factor ≥ 10 between July 1, 2010 and June 30, 2011 (n=96).
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G. Secondary Endpoint Sub-Analysis 
As a secondary analysis, we examined the likelihood of reporting statistically 
significant endpoints in corresponding publications for the 1040 secondary efficacy 
endpoints listed on ClinicalTrials.gov. Statistical significance could not be determined for 
184 (18%) endpoints because results were not reported on ClinicalTrials.gov, the trial 
only contained one arm, or results were in the form of a median or other summary 
statistic that required the underlying distribution to determine statistical significance, 
and no statistical analysis was provided on ClinicalTrials.gov. Among the remaining 856, 
384 (45%) were statistically significant. However, only 559 (65%) of these 856 secondary 
endpoints were reported in the publication, and secondary endpoints with statistically 
significant results were more likely to be published when compared with endpoints 
whose results were not statistically significant (71% versus 61%; Odds Ratio=1.60, 95% 
CI=1.20-2.13, P=0.001).  
 
H. Safety Outcome Registry-Article Comparison 
Among 95 trials with adverse events results in both sources, we could not 
compare serious adverse events for 33 (36%) and other adverse events for 31 (33%), 
most often because of differences in severity stratification between the two sources. 
Among 62 trials with comparable serious adverse events, 39 (63%) were discordant, 
because of differing event criteria or frequency of reported serious adverse events. 
Among 64 trials with comparable other adverse events, 46 (72%) were discordant, 
 
 46 
because of differing event criteria, frequency, or frequency reporting threshold of 
reported other adverse events. Overall, only 14 of 96 trials (15%) had concordant 





VII. DISCUSSION  
A. Summary  
In a sample of 96 trials published during a recent one-year period in high-impact 
journals that were registered within and reported results on ClinicalTrials.gov, we found 
that results reporting information available on ClinicalTrials.gov, including descriptions 
of the study cohort and intervention, as well as primary and secondary outcomes and 
safety outcomes, was complete for more than 90% of registered trials. However, upon 
comparing this information to the information provided in corresponding published 
articles, nearly every trial had at least one discrepancy in the results descriptions or 
values reported on ClinicalTrials.gov. Moreover, in many instances, results for both 
sources could not be compared because of differences in the presentation or analysis of 
the results. Our findings raise concerns about whether and which of the results 
reported on ClinicalTrials.gov or in published articles were accurate and about the 
usefulness of current clinical trial result reporting efforts to inform research and 
practice, as publicly reported results at times disagree with, or even contradict, findings 
reported in the peer-reviewed literature. 
Many of the discrepancies between results reported on ClinicalTrials.gov and in 
the published articles had important implications for clinical practice and interpretation 
of trial findings. For instance, for some trials, the study intervention differed between 
what was reported on ClinicalTrials.gov and the published article, leading to uncertainty 
over how to interpret the results for practice. Similarly, a third of discordantly reported 
primary outcome results led to different trial interpretation between the two sources 
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and no discrepancy of this nature should ever occur. Discrepant primary outcome 
definitions and results have obvious potential to confuse or potentially mislead 
investigators, clinicians, and patients about the effectiveness of an intervention. 
However, it is also important to note that many of the discrepancies observed were not 
clinically meaningful. For instance, we observed minor discrepancies in the number of 
subjects studied as well as in the results values reported for primary and secondary 
outcomes and safety outcomes, many of which did not lead to different trial 
interpretation between the two sources. 
 
 B. Setting in the Developing Literature 
As compared to studies done prior to ours, our findings were similar in terms of 
demonstrating outcome reporting bias in the published literature. Ewart et al., for 
instance, found just over 30% of primary outcomes differed between trial registry – 
including, but not limited to, ClinicalTrials.gov – and publications in high-impact journals 
in a cross-section examined in 2007, before the passing of FDAAA.49 While we found 
15% of primary outcomes were described discordantly between ClinicalTrials.gov and 
the high-impact publications in our sample, it is promising that our rate was 
approximately half of that found by Ewart et al. now that the FDAAA mandates are in 
place. 
Since the completion of our study, similar studies have come out in the 
literature. In one, by Hartung et al., clinical trial results reported on ClinicalTrials.gov 
were compared to those reported in corresponding journal publications for a random 
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sample of phase 3 and 4 clinical trials.77 Unlike our study, which examined studies in the 
highest-impact journals that likely represented a “best-case” scenario, this trial 
examined a random sample with trials published in a variety of journals. Strikingly, and 
reassuringly, our results were highly consistent with those uncovered by Hartung and 
colleagues.  
Indeed, Hartung and colleagues found that 15% of trials reported discrepant 
primary outcome descriptions between ClinicalTrials.gov and corresponding 
publications, whereas 20% inconsistently reported primary outcome values.77 We found 
that 15% of primary outcomes were described inconsistently between ClinicalTrials.gov 
and corresponding publications and 16% of primary results values were discordant 
between the two sources. Hartung and colleagues also found that 35% of trials had 
reporting discrepancies for serious adverse events.77 We, too, found that 41% of trials 
had discrepant serious adverse event reporting. As in our study, this group similarly 
found that inconsistencies were frequently due to underreporting or omission of 
adverse events from publications. Whereas Hartung and colleagues found that 37% of 
trials with at least one frequently reported adverse event in ClinicalTrials.gov had 
discrepant adverse event reporting, we found slightly higher rates of these 
discrepancies.77 Although the results reported on ClinicalTrials.gov and in corresponding 
publications are not yet consistent, it is reassuring that the studies examining this issue 
are. 
Similarly, Killeen et al. published a study in Annals of Surgery to compare trial 
registration and primary outcome reporting in trials published specifically in surgery 
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journals.78 Like ours, their sample came from studies published in the ten surgical 
journals with the highest impact factors, and all were either members of the ICMJE or 
specifically required trial preregistration as a prerequisite to publication. However, the 
trials in this sample were registered in several different clinical trial registries, including, 
but not limited to, ClinicalTrials.gov. They found that that fewer than half of the 246 
trials in their sample were adequately registered on ClinicalTrials.gov, which included 
those that were registered after the study completion as well as those that did not have 
a primary endpoint, had an unclear primary endpoint, or had a primary endpoint 
without a defined timepoint in the registry entry.78 Among the 108 trials deemed to be 
“adequately registered,” the group found that nearly 30% had a discrepancy between 
the registered and published primary outcome, a number about twice as high as that 
found in our sample of trials published across specialties.78 Among those results that 
could be compared, the group found the discrepancy favored a positive result in over 
90% of cases – a high, but perhaps not surprising, number.78 This finding was in line with 
our secondary endpoint sub-analysis, which also suggested positive outcome reporting 
bias among publications, as well as with previous findings in the literature.7 Another 
study by Chahal et al. examining 34 clinical trials of operative and non-operative 
interventions in the field of orthopedic surgery registered in ClinicalTrials.gov and 
reported in publications showed that 80% had at least one discrepant piece of 
information between the two sources, with 35% of trials having a discordance between 
the registered and published primary endpoint.79 As shown by these two recent studies, 
the findings in the specifically surgical world are not far off from, if not wrought by more 
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discrepancy than, those in the high-impact general medical literature as demonstrated 
by our work.  
 
C. Implications 
There are several possible explanations for the discrepancies we observed 
between the results information and values reported on ClinicalTrials.gov and in 
published articles. The most likely cause of these differences is reporting and 
typographical errors. Results reporting is a relatively new phenomena and is the 
responsibility of trial investigators and funders, who are less experienced with public 
dissemination of their findings and may in fact have become accustomed to a system 
where journal editors provide critical peer review and data checks to ensure accuracy. 
Similarly, the space available to report results in published articles is limited, potentially 
leading to incomplete reporting in articles while complete reporting is available on 
ClinicalTrials.gov. While this explanation may justify some discrepancies in adverse 
event reporting, particularly less serious adverse events, which have been shown to be 
less likely to be published,80 it cannot account for the sizable discrepancy in secondary 
endpoint reporting. Other possibilities include differing reporting requirements, such 
that the format required by ClinicalTrials.gov may have differed from the journals, 
possibly leading to re-analysis and error; or that results might have been posted to 
ClinicalTrials.gov before the trial was completed, or alternatively have been published 
before the final data set was locked. 
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Lastly, and most worrisomely, discrepancies may also be due to investigators and 
funders disseminating more favorable findings in published articles, which are more 
likely to be read by clinicians and influence practice. We determined that statistically 
significant secondary endpoint results were more likely to be included in published 
articles, suggesting that investigators or publishers may be biased in the selection of 
endpoints to include in publications. Thus, our work, along with the other recent 
findings in the literature, raises important concerns that even with clinical trial 
registration and results reporting, selective result reporting continues to distort the 
medical evidence published in biomedical journals. Other examples of selectively 
reporting favorable outcomes, even despite public availability of trial findings through 
alternative sources, have been described.7,37,42,47-50,52 
ClinicalTrials.gov has great potential to ensure the availability of complete and 
comprehensive results of all studies investigating medical products to inform and 
improve the practice of evidence-based clinical medicine, addressing known problems 
with the slow and incomplete dissemination of research findings via peer-reviewed 
published articles.22,38,39,41,81 However, our study raises questions about the accuracy of 
the reported information, suggesting that further efforts are needed to improve the 
information being made available to investigators, clinicians, and patients. One solution 
may be to provide training to investigators and funders in the complete and accurate 
reporting of trial results, or simply to increase the resources available to 
ClinicalTrials.gov so that the organization could hire staff to input results for reporting. 
Another may be to offer external peer review of the reported results, providing 
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independent review of study reports before public results reporting. Alternatively, 
review of the results on ClinicalTrials.gov could be routinely undertaken by journal 
editors and reviewers upon receiving a trial for submission for publication. Finally, 
perhaps investigators could make their clinical trial data available for public use, 
allowing independent verification of the reported results,82 or at least Clinical Study 
Reports or trial protocols, which can be similarly scrutinized and provide substantially 
more information than published articles.31,52 
 
D. Limitations 
There are important limitations that must be considered when interpreting our 
analysis. First, our study was limited to clinical trials that were registered and reported 
results on ClinicalTrials.gov and had main results published in high-impact journals. 
Despite studying a one year period, our sample for analysis only included 96 trials. 
Moreover, since half of registered studies are never published41 and high-impact 
journals are members of the International Committee of Medical Journal Editors, which 
has been requiring clinical trial registration for nearly 10 years,16 our study may 
represent the best case scenario in terms of the completeness and accuracy of results 
reporting. Nevertheless, in this early period after FDAAA enactment when few trials are 
reporting results,68 our results can be used to inform and improve the results reporting 
system being used by ClinicalTrials.gov, ensuring its impact on clinical research and 
practice. Additionally, we were conservative in our determination of results 
concordance and discordance. We did not compare results when reporting was 
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numerical in one source but graphical in the other, sources differed in statistical analysis 
method, or results were stratified differently between the sources. Moreover, even 
when differences were observed, we were cautious when determining whether these 
differences would lead to different trial interpretation. 
 
E. Conclusion 
In conclusion, among trials published during a recent one year period in high-
impact journals that were registered within and reported results on ClinicalTrials.gov, 
we found that results reporting information available on ClinicalTrials.gov was 
predominantly complete. However, upon comparing this information to corresponding 
published articles, nearly every trial had at least one discrepancy in the results 
descriptions or values reported on ClinicalTrials.gov, questioning the accuracy of both 
sources and raising concerns about the usefulness of results reporting to inform clinical 
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Appendix Table A1: Trial intervention descriptions reported on ClinicalTrials.gov and in the corresponding 
journal article that were determined to be discordant (n=15). 
ClinicalTrials.gov 
Identifier 
Trial Intervention Descriptiona Trial Intervention 
Discrepancy 
Explanation 
ClinicalTrials.gov Published Article 
NCT00099268 Carbidopa/Levodopa/Entacapone: 
Patients received Carbidopa/ 
levodopa/entacapone tablets. The 
study was designed as a flexible 
dose trial (200-1000 mg/day 
levodopa). The target dose was 
400 mg/day levodopa 
administered orally as 4 equal 
doses 4 times a day with 3.5-hour 
dosing intervals for a treatment 




both groups was 
initiated at a dose of 
50/12.5mg twice 
daily, and titrated 
to 100/25 (target 
dose) or 
150/37.5mg 4x daily 
administered at 3.5-
hour intervals. For 







states the levodopa 
dose is flexible, up to 
1000 mg/day, while 
the article lists three 
distinct doses with a 




received Immediate release 
carbidopa/levodopa tablets. The 
study was designed as a flexible 
dose trial (200-1000 mg/day 
levodopa). The target dose was 
400 mg/day levodopa 
administered orally as 4 equal 
doses 4 times a day with 3.5-hour 
dosing intervals for a treatment 
period of 134 to 208 weeks. 
administered 
with each LC dose. 
NCT00108953 Sorafenib + Doxorubicin: 
"Sorafenib + Doxorubicin" -- 
combination therapy: Sorafenib 
(Nexavar, BAY43-9006) 200 mg 
tablets by mouth (orally) twice 
daily + doxorubicin 60 mg/m2 
intravenous infusion every 21 
days for 6 cycles (18 weeks). 
 
Placebo + Doxorubicin: "Placebo + 
Doxorubicin" -- monotherapy: 
Sorafenib (Nexavar, BAY43-9006) 
matching placebo tablets by 
mouth (orally) twice daily + 
doxorubicin 60 mg/m2 
intravenous infusion every 21 
days for 6 cycles (18 weeks). 




21 days for a 
maximum of 360 
mg/m2 plus either 
400 mg of sorafenib 








does not state 
number of 200 mg 
tablets and thus 
suggests Sorafenib 
and placebo dosing 
at 400 mg/day, while 
article states dosing 
is 800 mg/day for 
each. 
NCT00141102 Celecoxib: 200 milligrams (mg) 







placebo and diclofenac slow 
release (SR) placebo 
 
Oral Diclofenac Plus Omeprazole: 
Oral diclofenac SR (75 mg BID) 
plus omeprazole (20 mg once 
daily [QD]) and celecoxib placebo. 
 
in a 1:1 ratio to 
receive either 
celecoxib 200 mg 
twice a day (Pfizer 
Inc, New York, NY, 
USA) or diclofenac 
slow release 75 mg 
twice a day 
(Novartis 
Pharmaceuticals UK 
Ltd, Camberley, UK) 
plus omeprazole 20 
mg once a day 
(AstraZeneca LP, 
Westborough, MA, 
USA) for 6 months. 
 
Additional celecoxib 
placebo is described 
on ClinicalTrials.gov 
and not in the 
article. 
NCT00154310 Everolimus + Mycophenolate 
Sodium: Everolimus tablets orally 
twice a day to maintain a level of 
6- 10 ng/mL and enteric-coated 
mycophenolate sodium orally 
twice a day to achieve a target 
dose of 1440 mg/day. 
Corticosteroids were added to the 
immunosuppressive regimen with 
a minimum dose of 5 mg 
prednisolone or equivalent and 
had to be continued throughout 
the first year. Cyclosporine 
Everolimus (0·75 mg 
twice a day, orally) 
was started the 




done in a stepwise 
manner (step 1: 
50%, 
step 2: 25%, step 3: 










the article, the 
everolimus dosing 
(0.75 mg twice daily) 
is enumerated only 
in the article and not 
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withdrawal started from Month 
4.5 post-transplant. 
 
Cyclosporine + Mycophenolate 
Sodium: Cyclosporine tablets 
orally twice a day to achieve 
protocol specific target levels and 
enteric-coated mycophenolate 
sodium orally twice a day to 
achieve a target dose of 1440 
mg/day. Corticosteroids were 
added to the immunosuppressive 
regimen with a minimum dose of 
5mg prednisolone or equivalent 
and had to be continued 
throughout the first year. 
concentrations of 
everolimus were 3–
8 ng/mL in step 1 




were based on 
either C-0h (trough 
concentration) or C-
2h (drug 
concentration 2 h 
after dose) in whole 
blood, according to 
local practice. Up to 
month 4·5 (time of 
randomisation), C-
0h target was 150–
220 ng/mL, and C-
2h were 1100–1400 
ng/mL for month 1, 
950–1300 ng/mL for 
month 2, and 800–
1200 ng/mL for 
month 3 onwards. 
From months 4·5–6 
after 
transplantation, 
C-0h (and C-2h) 
on ClinicalTrials.gov. 
Cyclosporine 
numerical dosage is 
not specified on 
ClinicalTrials.gov, 
while the target 
levels are detailed in 





1000 ng/mL), and 














sodium was 1440 
mg/day, orally, for 
both groups 




NCT00171210 Crossover: Participants treated 
with Deferoxamine (DFO) during 
the core study and crossed over 
to receive Deferasirox (ICL670) 









Basis of dosage is 
described as body 
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extension study. Dosage based on 
body weight. 
 
ICL670: Participants treated with 
Deferasirox (ICL670) orally once a 
day during the core study and 
continued this treatment in the 
extension study. Dosage based on 
body weight. 
the start of 
deferasirox 
treatment, whereby 
patients with LIC 
values of 2-3, > 3-7, 
> 7-14, and > 14 mg 
Fe/g dry weight (dw) 
were assigned 
deferasirox doses of 





LIC in the article. 
NCT00177671 Donepezil: Treatment with 
antidepressants (escitalopram 
(10mg to 20mg daily), venlafaxine 
(150mg to 300mg daily), 
duloxetine (20mg to 120mg daily) 
plus donepezil (5mg to 10mg 
daily). 
 
Placebo: Treatment with 
antidepressants (escitalopram 
(10mg to 20mg daily), venlafaxine 
(150mg to 300mg daily), 







oxalate (≤20 mg/d). 
Those not 
responding 
fully were switched 















only and aripiprazole 




mg/d) to achieve full 
response. 
NCT00197106 Salmeterol/FP 50/100 Mcg Plus 
Placebo: One puff Salmeterol/FP 
50/100 mcg plus one puff placebo 
(matching one puff of FP in the 





either FP, 200 mg 
twice a day Diskus 
(FP group), or 
salmeterol/FP, 
50/100 twice a day 
Diskus (SFP group), 









Early Locomotor Training 
Program: Stepping on a treadmill 
with partial body weight support 
and manual assistance as needed 
for 20-30 minutes at 2.0 mph, 
followed by a progressive 
overground walking program for 
20 minutes delivered at 2 months 
post-stroke. 
 
Late Locomotor Training Program: 
Stepping on a treadmill with 
partial body weight support and 
manual assistance as needed for 
20-30 minutes at 2.0 mph, 
followed by a progressive 
Locomotor training 
included stepping on 
a treadmill with 
partial body-weight 
support and manual 
assistance as 
needed for 20 to 30 
minutes at 3.2 km 
per hour (0.89 m per 
second [2.0 mi per 
hour]), followed by a 
progressive program 
of walking over 






program is described 
as lasting 20 minutes 
on ClinicalTrials.gov 




overground walking program for 




First line antiretroviral regimen 
monitored by a HIV-trained 
medical doctor: 
1) Stavudine (>60 kg: 40 mg twice 
daily and <60 kg: 30 mg twice 
daily) 
2) Lamivudine (150mg twice daily) 
and  
3) Efavirenz (600mg daily). For 
women of child bearing potential 
with a CD4+ count <250 
cells/mm3, Nevirapine (200 mg 
daily x 14 days, then 200 mg twice 
daily) and for women with a CD4+ 





the clinical safety 
team included a 
nucleoside 
backbone 
of stavudine and 
lamivudine, with a 
choice of efavirenz, 
nevirapine, or 
lopinavir plus 
ritonavir. The initial 
dose of stavudine 
was 40 mg daily for 
individuals weighing 
more than 60 kg, 
which was reduced 
to 30 mg for all 
patients 
from mid-2007 in 
line with WHO 
recommendations. 
Efavirenz was the 
preferred non-
nucleoside for men 






dosage is 80 mg or 
60 mg per day, while 
article states dosage 




wishing to become 
pregnant and willing 









nevirapine if their 
CD4+ lymphocyte 
count was less than 
250 cells per μL, or 
lopinavir plus 
ritonavir if their 
count was 250 cells 
per μL or greater. 
Pregnant women, 
who were allowed 
to enrol after their 





NCT00298766 Single Agent VELCADE: 
Bortezomib 0.7, 1.0, 1.3 and 1.6 
Patients were 





mg/m^2 once weekly (QW) 4 
doses in a 5 week cycle, and 0.7, 
1.0, 1.3 mg/m^2 twice weekly 
(BIW) 4 doses in a 3 week cycle 
  
bortezomib at doses 
up to 1.6 mg/m2 on 
days 1, 8, 15, and 22 
of 35-day cycles 
(once-weekly 
regimen) and then 
at doses up to 1.3 
mg/m2 on days 1, 4, 
8, and 11 of 21-day 
cycles (twice-weekly 
regimen); details of 
the phase 1 dose-
escalation 
component 
have been reported 
previously. 
 
The article lists that 
there are dosages up 
to the maximum 
dose, but only 
enumerates the 
maximum dose for 
each cycle, while 
ClinicalTrials.gov 
enumerates all dose 
amounts. 
NCT00423670 PegIntron (1.5 μg/kg, once 
weekly [QW]) plus ribavirin (800 
to 1400 mg/day) for 48 weeks.  
Part 1 consisted of 
five treatment 
groups: one was a 




2b 1·5 μg/kg plus 
ribavirin 800–1400 
mg per day for 48 
weeks (PR48). Two 





PegIntron 1.5 μg/kg 
dosage is described 
as once weekly on 
ClinicalTrials.gov but 
appears to be daily 




2b 1·5 μg/kg and 
ribavirin 800–1400 




Indacaterol 150 μg (Continued 
Into Stage 2): In the morning, 
Indacaterol 150 µg once daily 
orally inhaled via a single dose dry 
powder inhaler (SDDPI) + Placebo 
to Indacaterol delivered via 
SDDPI + Placebo to Formoterol 
delivered via Aerolizer. In the 
evening, Placebo to Formoterol 
delivered via Aerolizer. 
Participated in the 2 week Stage 1 
and continued treatment up to 26 
weeks in Stage 2. Placebo to 
Formoterol inhalation in the 
morning and in the evening was 
discontinued after Stage 1. 
 
Indacaterol 300 µg (Continued 
Into Stage 2): In the morning, 
Indacaterol 300 µg once daily 
orally inhaled via a SDDPI + 
Placebo to Indacaterol delivered 
via SDDPI + Placebo to 
Formoterol delivered via 
Patients received 
double-blind 
indacaterol 150 or 
300 mg or placebo 
via single-dose dry 
powder inhaler, or 
open-label 






was not available.) 
Treatments were 
taken once daily at 





to Indacaterol is 
described on 
ClinicalTrials.gov but 
not in the article. 
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Aerolizer. In evening, Placebo to 
Formoterol delivered via 
Aerolizer. Participated in the 2 
week Stage 1 and continued 
treatment up to 26 weeks in 
Stage 2. Placebo to Formoterol 
inhalation in the morning and in 
the evening was discontinued 
after Stage 1. 
 
Tiotropium 18 µg (Continued Into 
Stage 2): Tiotropium 18 µg dry 
powder capsules delivered (open 
label) via manufacturer's 
proprietary SDDPI, (Handihaler®). 
Participated in the 2 week Stage 1 
and continued treatment up to 26 
weeks in Stage 2. 
 
Placebo (Continued Into Stage 2): 
In the morning, Placebo to 
Indacaterol delivered via two 
SDDPI devices + Placebo to 
Formoterol delivered via 
Aerolizer. In the evening, Placebo 
to Formoterol delivered via 
Aerolizer. Participated in the 2 
week Stage 1 and continued 
treatment up to 26 weeks in 
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Stage 2. Placebo to Formoterol 
inhalation in the morning and in 
the evening was discontinued 
after Stage 1. 
NCT00551642 Inhaled Nitric Oxide (NO): Inhaled 
NO administered by nasal 
continuous positive airway 
pressure, nasal cannula or face 
mask at 5 parts per million (ppm) 
for a maximum of 21 days 
 
Placebo (Nitrogen): Placebo 
Nitrogen gas administered by 
nasal continuous positive airway 
pressure, nasal cannula or face 
mask at 5 parts per million for a 
maximum of 21 days 
Infants were given 
inhaled nitric oxide 




given for at least 7 
days, up to a 
maximum of 21 
days. If patients 
needed mechanical 
ventilation for less 
than 7 days, therapy 
was completed 
through a nasal 
continuous positive 





The article lists a 
minimum and 
maximum duration 
of inhaled NO, but 
ClinicalTrials.gov 
reports only a 
maximum, implying 
there is no minimum 
duration. 
NCT00642174 Prasugrel Then Clopidogrel: 
Prasugrel: Oral prasugrel 60-mg 
loading dose, followed by 6 to 9 
days of prasugrel 10-mg/day 
tablet maintenance dose. 
Clopidogrel: Oral clopidogrel 600-
mg loading dose, followed by 6 to 
Patients who met all 
criteria for 
enrolment were 
randomized at the 
first visit to double-
blind treatment of 
either prasugrel 60 
Description of 
placebo & Duration 
of administration 
 
Placebo tablets are 
described in the 
article but not on 
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9 days of clopidogrel 150-mg/day 
tablet maintenance dose. 
 
Clopidogrel Then Prasugrel: 
Clopidogrel: Oral clopidogrel 600-
mg loading dose, followed by 6 to 
9 days of clopidogrel 150-mg/day 
tablet maintenance dose. 
Prasugrel: Oral prasugrel 60-mg 
loading dose, followed by 6 to 9 
days of prasugrel 10-mg/day 
tablet maintenance dose. 
mg LD 
orally followed by 10 
mg/day MD for 7 
days or clopidogrel 
600 mg LD orally [75 






USA)] followed by 
150 mg/day MD for 
7 days (Figure 
1A)…Patients were 
administered an 
equal number of 
identical tablets for 
either the LDs (six 
prasugrel 10 mg 
tablets and eight 
placebo tablets 
or eight clopidogrel 
75 mg tablets and 
six placebo tablets) 
or MDs (one 
prasugrel 10 mg 
tablet and two 
placebo tablets or 
ClinicalTrials.gov. 
ClinicalTrials.gov 
states that dose 
duration is 6 to 9 
days, while the 





two clopidogrel 75 
mg tablets and one 
placebo tablet). 
NCT00703118 T12/PR48: 12 weeks of 750 mg 
telaprevir q8h followed by 4 
weeks of Placebo in combination 
with 48 weeks of Peg-IFN-alfa-2a 
and RBV at standard doses 
 
T12(DS)/PR48: 4 weeks of Placebo 
followed by 12 weeks of 750 mg 
telaprevir q8h in combination 
with 48 weeks of Peg-IFN-alfa-2a 
and RBV at standard doses 
 
Pbo/PR48: 48 weeks of Peg-IFN-




orally at a dose of 
750 mg every 8 
hours; 
peginterferon alfa- 
2a (Pegasys, Roche) 
was administered 
subcutaneously at a 
dose of 180 μg per 
week; and ribavirin 
(Copegus, Roche) 
was administered 
orally at a dose of 
1000 to 1200 mg 
per day… In the 
T12PR48 group, 266 
patients were 
assigned to receive 
telaprevir, 
peginterferon, and 
ribavirin for 12 
weeks, followed by 
placebo plus 
peginterferon 
and ribavirin for 4 
Description of 
placebo & Dosage of 
intervention 
 
Additional placebo is 
described for the 
PR48 (control) group 
in the article, but not 
on ClinicalTrials.gov. 
ClinicalTrials.gov 
reports only that 
doses are standard, 
while the article 
specifies numeric 
values for dosing. 
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weeks, and then 
peginterferon plus 
ribavirin alone for 
32 weeks. In the 
lead-in T12PR48 
group, 264 patients 
were assigned to 
receive placebo, 
peginterferon, and 
ribavirin for 4 
weeks, followed by 
telaprevir plus 
peginterferon 
plus ribavirin for 12 
weeks, and then 
peginterferon plus 
ribavirin alone for 
32 weeks. In the 
PR48 (control) 
group, 132 patients 
were assigned to 
receive placebo, 
peginterferon, and 
ribavirin for 16 
weeks, followed by 
peginterferon plus 
ribavirin for 32 
weeks. In all the 




for 48 weeks.  
a Entries in the Trial Intervention Description columns are taken verbatim from ClinicalTrials.gov and the corresponding article, 




Appendix Table A2: Primary efficacy outcome results values reported on ClinicalTrials.gov and in the corresponding journal article 





Primary Efficacy Outcome Results Difference in Trial 
Interpretation due to 
Discrepancy? 
















qHPV Vaccine: 0.1 
Placebo: 1.0 
Percent relative risk 
reduction: 90.6  
95% CI: (70.1, 98.2) 
qHPV Vaccine: 0.11 
Placebo: 1.10 
Observed efficacy:  
90.4%  






The incidence values 
and observed efficacy 
are very similar 
between sources, 
likely with a similar 









Pain Crisis (VOC), 
median hours 
(95% CI) 
Inhaled Nitric Oxide: 61.83  
95% CI: (41.75, 78.00) 
Placebo: 55.16  
95% CI: (46.00, 72.00) 
No statistical analysis 
provided. 
Inhaled Nitric Oxide: 73.0  
95% CI: (46.0, 91.0) 
Placebo: 65.5  
95% CI: (48.1, 84.0) 
P = 0.87 
Yes 
 
The time to resolution 
in both groups is 
substantially lower on 
ClinicalTrials.gov than 
in the article, with the 
treatment time on 
ClinicalTrials.gov 
lower than the 
placebo time in the 
article, even if the test 
of statistical 
significance was likely 







Sorafenib + Doxorubicin:  
263 days  
95% CI: (146, 384) 
Placebo + Doxorubicin:  
147 days  
95% CI: (66, 244) 
Sorafenib + Doxorubicin:  
6.4 months  
95% CI: (4.8, 9.2) 
Placebo + Doxorubicin:  
2.8 months  
95% CI: (1.6, 5) 
Yes 
 
The median time to 
progression in both 
groups is substantially 
higher on 
ClinicalTrials.gov (9.6 
and 4.8 months, 
respectively), even if 
the test of statistical 
significance between 
the groups was the 
same in both sources. 
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Donepezil: 19/67  
95% CI: (16, 31) 
Placebo: 11/63  
95% CI: (6, 18) 
HR = 3.97  
SD = 2.09 
95% CI: (1.00, 4.41) 
P = 0.05 
Donepezil: 35%  
95% CI: (24%, 46%) 
Placebo: 19%  
95% CI: (9%, 29%) 
HR = 2.09 
95% CI: (1.00, 4.41) 
λ2=3.97  




The percentage of 
participants with 
major depression 
recurrences is lower 
(28.4% and 17.5%, 
respectively) on 
ClinicalTrials.gov than 
in the article, and the 
hazard ratio listed on 
ClinicalTrials.gov is 2-
fold higher than that 
listed in the article 





at 4 Hours Post-
Dose, mean units 




Ecallantide: 46.8  
SD: 59.3 






score and difference 
between arms is 
similar in both 




P = 0.037 
 
P = 0.004 
 
significance shows a 
significant difference 









981.0  days 




1212.0 days  




32.8 months  




51.8 months  




PFS is substantially 
lower in the rituximab 
arm reported on 
ClinicalTrials.gov (39.8 
months) than in the 
article, even if the test 
of statistical 
significance is the 




of CV Death / MI 
/ Stroke - ASA 
Clopidogrel + ASA Low 
Dose: 












Clopidogrel + ASA High 
Dose:  
527/12,498 
P = 0.6047 
Clopidogrel + ASA High Dose:  
530/12,507 
P = 0.61 
with nearly identical 
tests of significance, in 
the two sources. 
NCT00377260 
 
The Time to 
Resolution of 
Symptoms, 













No statistical analysis 
provided for this timepoint. 
Amoxicillin-Clavulanate: 61% 
Placebo: 54% 
No statistical analysis 






respectively) are very 
similar to those in the 
article, likely with a 





























No statistical analysis 
provided for this timepoint. 
No statistical analysis 
provided for this timepoint. 
and 72.1%, 
respectively) are very 
similar to those in the 
article, likely with a 




The Time to 
Resolution of 
Symptoms, 














No statistical analysis 
provided for this timepoint. 
Amoxicillin-Clavulanate: 41% 
Placebo: 36% 
No statistical analysis 






respectively) are very 
similar to those in the 
article, likely with a 








The Time to 
Resolution of 
Symptoms, 
















No statistical analysis 
provided for this timepoint. 
Amoxicillin-Clavulanate: 67% 
Placebo: 53% 
No statistical analysis 






respectively) are very 
similar to those in the 
article, likely with a 








Glucosamine Sulphate: 9, 
SD: 4;  
Placebo: 9, SD: 4 
Odds Ratio: 4.5 ± 4; P=0.05 
Glucosamine Sulphate: 4.8, 
95% CI: (3.9, 5.6) 





is higher for both trial 
arms and statistical 
testing results are 
different in the two 
sources, leading to a 
























Groups (1 Mcg 
and 2 Mcg), 
mean log mg/g 
creatinine 
Placebo: -0.03  
SD: 0.61 
Combined Paricalcitol 1 
Mcg and 2 Mcg: -0.18  
SD: 0.70 
Paricalcitol 1 Mcg: -0.15  
SD: 0.72 
Paricalcitol 2 Mcg: -0.22  
SD: 0.69 
Placebo vs. Combined 
Paricalcitol 1 Mcg and 2 
Mcg:  
P = 0.071 
Placebo: -3%  
95% CI: (-16, 13) 
Combined Paricalcitol 1 Mcg 
and 2 Mcg: -16%  
95% CI: (-24, -9) 
Paricalcitol 1 Mcg: -14%  
95% CI: (-24, -1) 
Paricalcitol 2 Mcg: -0.20%  
95% CI: (-30, -8) 
Placebo vs. Combined 
Paricalcitol 1 Mcg and 2 Mcg:  
P = 0.071 
Placebo vs. Paricalcitol 1 Mcg: 
No 
 
Change from baseline 
UACR levels are very 
similar with identical 
tests of significance. 
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Placebo vs. Paricalcitol 1 
Mcg: 
P = 0.229 
Placebo vs. Paricalcitol 2 
Mcg: 
P = 0.053  
 
P = 0.23 
Placebo vs. Paricalcitol 2 Mcg: 
















Eptifibatide: 124/214  
Abciximab: 103/196 
Adjusted Difference: 6.8% 
95% CI: (-3.0%, 16.6%) 
Eptifibatide: 62.6% 
Abciximab: 56.3% 
Adjusted Difference: 7.1% 
95% CI: (2.7%, 17.0%) 
Yes 
 
Confidence interval of 
the adjusted 
difference between 
arms crosses zero on 
ClinicalTrials.gov and 
does not in the article, 
suggesting a 
difference in the 
statistical significance 
of the results between 





Rate of Change 
on the ADAS-Cog 
11, mean 
Placebo: 7.98  
SD: 9.84 
Docosahexaenoic Acid 
(DHA): 8.27   
SD: 8.9 
No statistical analysis 
provided. 
Placebo: 8.27  
95% CI: (6.72, 9.82) 
Docosahexaenoic Acid (DHA): 
7.98   
95% CI: (6.51, 9.45) 
P = 0.41 
No 
 
While values appear 
to be switched for the 
DHA and placebo 
arms between the 
two sources, 
interpretation is 
unchanged since the 
difference between 
values is not 
statistically significant.  
NCT00440050 
 
Rate of Change 
on CDR-SOB 
Placebo: 2.87  
SD: 2.93 
Docosahexaenoic Acid 
(DHA): 2.93  
SD: 2.83 
No statistical analysis 
provided. 
Placebo: 2.93  
95% CI: (2.44, 3.42) 
Docosahexaenoic Acid (DHA): 
2.87   
95% CI: (2.44, 3.30) 
P = 0.68 
No 
 
While values appear 
to be switched for the 
DHA and placebo 
arms between the 
two sources, 
interpretation is 
unchanged since the 
difference between 













TAXUS Element: 51/915 
TAXUS Express: 19/309 
P = 0.9996 
TAXUS Element: 52/922 
TAXUS Express: 19/313 




participants with TLF 
is similar between 
sources, and both 
sources report no 
significant difference 






Survival (PFS) at 
2 Years 
 
Lymphoma subjects: 13/29  
 
Lymphoma subjects: 47% (of 




The number of 
participants with PFS 
at 2 years is 
approximately the 
same in both sources 
(45% and 47%, 
respectively), even if 









Exenatide: -1.71  
SE: 0.09 
Placebo: -1.00  
Exenatide: -1.74  
95% CI: (-1.91, -1.56) 




change in HbA1c is 
very similar between 
sources, with an 
identical test of 
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percentage SE: 0.09 
P<0.001 
















P = 0.48 
No 
 
The number who 
achieved ROSC is 
similar between 
sources, likely with a 




Change in Daily 
Severity of Hot 
Flashes Between 
Baseline and 




Escitalopram:  -0.53  
95% CI: (-0.64, -0.40)  
Placebo: -0.30  
95% CI: (-0.42, -0.17) 
P<0.001 
Escitalopram:  -0.52  
95% CI: (-0.64, -0.40)  
Placebo: -0.30  




The change in daily 
severity of hot flashes 
in the escitalopram 
arm is very similar 
between sources, and 
the test of statistical 
significance is 
identical. 
 
 
 
 
